Resuscitation Uncertain: Can Debiopharm Help Revive Pfizer's Failed Melanoma Drug?
April 28, 2010
Resuscitation Uncertain: Can Debiopharm Help Revive Pfizer's Failed Melanoma Drug?
After pharmacogenetic analysis in a Phase II melanoma study for tremelimumab failed to yield any clinically meaningful gene-response markers, Pfizer inked a codevelopment deal with Debiopharm handing over Phase III development of the drug with a protein marker linked to response. But commercialization rights still belong to Pfizer.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- With New Hires to Pharma Business Development Team, Qiagen Prioritizes Rx/Dx Partnership Strategy
April 21, 2010 / Pharmacogenomics Reporter - Lab21 Offering Companion Testing to Personalize ALK Inhibitors for NSCLC Patients
February 22, 2012 / Pharmacogenomics Reporter - Diaceutics Report Sheds Doubt on Pharmas' Personalized Medicine Preparedness
June 15, 2011 / Pharmacogenomics Reporter - ODAC Meeting on Accelerated Approval for Oncologics Raises Questions about Strategies for PGx Drugs
February 16, 2011 / Pharmacogenomics Reporter - Cancer Research UK on Path to Building National Genetic Testing Service
February 16, 2011 / Pharmacogenomics Reporter